» Articles » PMID: 35542807

Probing the Origin of Estrogen Receptor Alpha Inhibition Large-scale QSAR Study

Overview
Journal RSC Adv
Specialty Chemistry
Date 2022 May 11
PMID 35542807
Authors
Affiliations
Soon will be listed here.
Abstract

Estrogen is an important component for the sustenance of normal physiological functions of the mammary glands, particularly for growth and differentiation. Approximately, two-thirds of breast cancers are positive for estrogen receptor (ERs), which is a predisposing factor for the growth of breast cancer cells. As such, ERα represents a lucrative therapeutic target for breast cancer that has attracted wide interest in the search for inhibitory agents. However, the conventional laboratory processes are cost- and time-consuming. Thus, it is highly desirable to develop alternative methods such as quantitative structure-activity relationship (QSAR) models for predicting ER-mediated endocrine agitation as to simplify their prioritization for future screening. In this study, we compiled and curated a large, non-redundant data set of 1231 compounds with ERα inhibitory activity (pIC). Using comprehensive validation tests, it was clearly observed that the model utilizing the substructure count as descriptors, performed well considering two objectives: using less descriptors for model development and achieving high predictive performance ( = 0.94, = 0.73, and = 0.73). It is anticipated that our proposed QSAR model may become a useful high-throughput tool for identifying novel inhibitors against ERα.

Citing Articles

Estrogen Receptor Alpha Binders for Hormone-Dependent Forms of Breast Cancer: e-QSAR and Molecular Docking Supported by X-ray Resolved Structures.

Masand V, Al-Hussain S, Alzahrani A, Al-Mutairi A, Hussien R, Samad A ACS Omega. 2024; 9(14):16759-16774.

PMID: 38617692 PMC: 11007693. DOI: 10.1021/acsomega.4c00906.


StackER: a novel SMILES-based stacked approach for the accelerated and efficient discovery of ERα and ERβ antagonists.

Schaduangrat N, Homdee N, Shoombuatong W Sci Rep. 2023; 13(1):22994.

PMID: 38151513 PMC: 10752908. DOI: 10.1038/s41598-023-50393-w.


MATH: A Deep Learning Approach in QSAR for Estrogen Receptor Alpha Inhibitors.

Pusparini R, Krisnadhi A, Firdayani Molecules. 2023; 28(15).

PMID: 37570812 PMC: 10421274. DOI: 10.3390/molecules28155843.


Mpropred: A machine learning (ML) driven Web-App for bioactivity prediction of SARS-CoV-2 main protease (Mpro) antagonists.

Ferdous N, Reza M, Hossain M, Mahmud S, Napis S, Chowdhury K PLoS One. 2023; 18(6):e0287179.

PMID: 37352252 PMC: 10289339. DOI: 10.1371/journal.pone.0287179.


StackBRAF: A Large-Scale Stacking Ensemble Learning for BRAF Affinity Prediction.

Syahid N, Weerapreeyakul N, Srisongkram T ACS Omega. 2023; 8(23):20881-20891.

PMID: 37332807 PMC: 10268632. DOI: 10.1021/acsomega.3c01641.


References
1.
Hall J, Couse J, Korach K . The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001; 276(40):36869-72. DOI: 10.1074/jbc.R100029200. View

2.
Palmieri C, Cheng G, Saji S, Zelada-Hedman M, Warri A, Weihua Z . Estrogen receptor beta in breast cancer. Endocr Relat Cancer. 2002; 9(1):1-13. DOI: 10.1677/erc.0.0090001. View

3.
Witkowska H, Carlquist M, Engstrom O, Carlsson B, Bonn T, Gustafsson J . Characterization of bacterially expressed rat estrogen receptor beta ligand binding domain by mass spectrometry: structural comparison with estrogen receptor alpha. Steroids. 1997; 62(8-9):621-31. DOI: 10.1016/s0039-128x(97)00047-0. View

4.
Roger P, Sahla M, Makela S, Gustafsson J, Baldet P, ROCHEFORT H . Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001; 61(6):2537-41. View

5.
Regan M, Viale G, Mastropasqua M, Maiorano E, Golouh R, Carbone A . Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006; 98(21):1571-81. DOI: 10.1093/jnci/djj415. View